Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average of $0.88

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.88 and traded as low as $0.63. Vaxart shares last traded at $0.66, with a volume of 1,919,722 shares.

Wall Street Analysts Forecast Growth

Separately, B. Riley raised Vaxart from a "neutral" rating to a "buy" rating and set a $2.00 target price for the company in a report on Wednesday, January 31st.

Vaxart Stock Performance

The stock has a market capitalization of $125.50 million, a PE ratio of -1.22 and a beta of 0.44. The business's 50-day moving average price is $1.11 and its 200 day moving average price is $0.88.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its earnings results on Thursday, March 14th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. The business had revenue of $3.25 million during the quarter, compared to analysts' expectations of $0.45 million. Vaxart had a negative return on equity of 108.45% and a negative net margin of 1,117.56%. As a group, equities research analysts predict that Vaxart, Inc. will post -0.45 earnings per share for the current year.

Hedge Funds Weigh In On Vaxart

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. PFG Investments LLC bought a new stake in Vaxart during the first quarter worth about $38,000. Kingswood Wealth Advisors LLC bought a new stake in Vaxart in the 1st quarter worth approximately $32,000. Beacon Capital Management LLC boosted its stake in Vaxart by 369.9% in the fourth quarter. Beacon Capital Management LLC now owns 50,814 shares of the biotechnology company's stock worth $29,000 after buying an additional 40,000 shares in the last quarter. Finally, AE Wealth Management LLC grew its position in Vaxart by 180.7% during the third quarter. AE Wealth Management LLC now owns 62,113 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 39,987 shares during the last quarter. Hedge funds and other institutional investors own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia.